Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.
You can change your choice at any time.
A large UCLA Health randomized clinical trial found that usual care via mailed FIT outreach outperformed active choice strategies in colorectal cancer screening uptake among adults aged 45 to 49 years, highlighting the challenges in engagin
Explore how carbohydrates, proteins, and fats affect fatty liver disease and learn evidence-based dietary and lifestyle recommendations to manage and reverse this common condition.
Linarin shows promise in mitigating NAFLD by enhancing autophagy via PI3K/Akt/mTOR inhibition, reducing inflammation, and restoring gut microbiota balance, alongside activating the PDE4D/cAMP/PKA/CREB pathway to improve hepatic lipid metabo
A comprehensive Swedish study reveals that patients with microscopic colitis face a significantly higher risk of developing psychiatric disorders such as depression and anxiety, underscoring the importance of holistic clinical management.
This multicentre trial shows sequential use of COX-2 inhibitors parecoxib and imrecoxib significantly reduces severe acute pancreatitis (SAP) incidence, shortens organ failure duration, lowers local complications, and decreases 30-day morta
A large multicohort study demonstrates that the China-CLIF framework outperforms existing criteria in diagnosing and predicting mortality in acute-on-chronic liver failure across all major aetiologies, with global applicability.
This study compares the risk of recurrent high-risk neoplasia after polypectomy in adults younger and older than 50, revealing similar elevated risks, supporting the extension of existing surveillance guidelines to younger adults.
A 6-week low FODMAP diet improves symptoms in functional dyspepsia/Postprandial Distress Syndrome, with variable individual triggers including glucose, though mucosal integrity remains unchanged.
Recent research elucidates how smoking modulates gut microbiota and immune responses differently in ulcerative colitis and Crohn’s disease, explaining its protective effect in UC but detrimental role in CD.
Explore how subtle liver symptoms can signal serious illness, the progression from hepatitis to liver cancer, and effective habits to protect your liver health.
Probiotic pretreatment improves Helicobacter pylori eradication rates and reduces side effects, offering a promising adjunctive strategy to overcome treatment challenges and antibiotic resistance.
Routine H. pylori screening after acute myocardial infarction does not significantly reduce upper gastrointestinal bleeding incidence; targeted screening in anemia or kidney failure subgroups may offer benefit.
In a large Swedish cluster-randomized trial, routine Helicobacter pylori screening after acute myocardial infarction did not significantly reduce upper gastrointestinal bleeding, though high-risk subgroups may benefit.
A large retrospective cohort study identifies a significant association between alopecia areata and increased risks of microscopic colitis, celiac disease, Crohn’s disease, eosinophilic esophagitis, and ulcerative colitis, highlighting the
This article explores how gastrointestinal diseases are linked to sleep disturbances, highlighting depression as a partial mediator and emphasizing the importance of addressing both gut and psychological health to improve sleep quality.
Recent evidence reveals gut dysbiosis-induced vitamin B6 metabolic disturbances as a novel, cortisol-independent mechanism driving chronic stress-related abnormal behaviors and inflammation, highlighting probiotic and vitamin B6 supplementa
The gut-skin axis embodies a bidirectional microbiota-influenced dialogue pivotal for tissue homeostasis and disease. Understanding this interplay reveals innovative approaches to manage inflammatory skin and gut diseases.
The HARMONY trial reveals that once-weekly efruxifermin significantly improves liver fibrosis without worsening MASH over 96 weeks, with a favorable safety profile supporting its phase 3 evaluation.
The phase 2 ION224-CS2 trial demonstrates that ION224, a DGAT2 antisense oligonucleotide, safely improves liver histology in MASH patients independent of weight loss, offering a potential new therapeutic approach.
Learn about five everyday foods that can damage your liver and discover effective habits to keep your liver healthy and functioning optimally.
Open language-specific specialty feeds and department pages.